GlobalData on MSN22h
Inceptor Bio doses first subject in trial of IB-T101 for renal cell carcinomaUS-based biotechnology company Inceptor Bio has dosed the first subject in the investigator-initiated trial of its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback